Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galeterone hydrochloride + F1
- Development stage
- Unknown
- Lead developer
- Tokai Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Galeterone hydrochloride + F1 is a small molecule therapeutic candidate being developed by LTN Pharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The drug is a multi-targeted androgen signaling inhibitor that acts through three distinct mechanisms: competitive antagonism of the androgen receptor (AR), inhibition of the CYP17A1 enzyme (17α-hydroxylase/C17,20-lyase) to block androgen synthesis, and induction of androgen receptor protein degradation. The 'F1' designation refers to a specific formulation or adjunct component designed to optimize the drug's pharmacokinetic profile or therapeutic efficacy. It is currently in Phase 2 clinical development for advanced prostate cancer indications.
- Other names
- galantamine hydrochloride + F1Gal HCL + F1-LTN Pharmaceuticals-mMCRPC
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)USP12/USP46 (Ubiquitin-specific peptidases 12 and 46)AR (Adrenergic receptors)
Beyond the preview
Go deeper on galeterone hydrochloride + F1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galeterone hydrochloride + F1.